title: The strategy of immunologic control of HIV-1 with structured treatment interruptions (STIs).
abstract: Structured treatment interruptions (STIs) have evolved as an experimental approach of interrupting highly active antiretroviral therapy (HAART) similar to cycles of cancer chemotherapy in order to develop immune control of HIV-1. There are multiple, ongoing clinical trials examining interruptions in antiviral therapy with and without immune-based therapies. If successful in developing immune control, STIs may be clinically useful but require large scale clinical trials to prove their utility and safety.
authors.affiliation: Immune Response Corporation, 5935 Darwin Court, Carlsbad, CA 92008, USA.
authors.forename: R B
authors.initials: RB
authors.lastname: Moss
authors.forename: F C
authors.initials: FC
authors.lastname: Jensen
authors.forename: D J
authors.initials: DJ
authors.lastname: Carlo
authors.forename: M R
authors.initials: MR
authors.lastname: Wallace
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology; D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology; D023241:Antiretroviral Therapy, Highly Active; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D015497:HIV-1 / Q000187:drug effects* / Q000276:immunology; D006801:Humans
chemical_list: D016915:AIDS Vaccines